Relationships between on-treatment changes in glial fibrillary acidic protein levels and clinical outcomes in patients with relapsing multiple sclerosis: post hoc analysis of the phase 3 ozanimod SUNBEAM trial

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2021
This article has no abstract
Epistemonikos ID: cfe3cbabda7ba90be291d47b2737d4d3500b644a
First added on: Apr 30, 2026